Clinical trials bring life extending and curative new treatments to cancer patients. Clinical drug trials play a vital role in moving new treatments to patients who need them most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients.
Learn more about clinical trials in this webinar with Dr. Isla Garraway of UCLA and the Greater Los Angeles VA, and Dr. Samuel Washington of UCSF.
There are currently nearly 100 Phase III trials and more than 500 Phase I/II trials related to prostate cancer in progress in the United States alone. Those that are approved will join the many drugs that have been approved for men with advanced/metastatic disease and further improve outcomes for patients:
Agent | Brand Name | Package Insert |
---|---|---|
abiraterone acetate | YONSA® | view PI |
abiraterone acetate | ZYTIGA® | view PI |
apalutamide | ERLEADA® | view PI |
cabazitaxel | JEVTANA® | view PI |
darolutamide | Nubeqa® | view PI |
denusomab | XGEVA® | view PI |
enzalutamide | XTANDI® | view PI |
lutetium Lu 177 vipivotide tetraxetan | PLUVICTO® | view PI |
olaparib | LYNPARZA® | view PI |
pembrolizumab | KEYTRUDA® | view PI |
radium-223 | XOFIGO® | view PI |
relugolix | ORGOVYX® | view PI |
rucaparib | RUBRACA® | view PI |
sipuleucel-T | PROVENGE® | view PI |
talazoparib | TALZENNA® | view PI |
niraparib (+ abiraterone acetate) | AKEEGA® | view PI |
The resources on this page can direct you to clinical trials that are currently open for enrollment in your local area, as well as across the country. If you are considering a clinical trial, speak to your doctor about the potential benefits of participating in a trial so you can make an informed decision that is best for you.
Frequently Asked Questions (FAQs)
- How long does the average trial last?
- What if I am on other medication(s) from my regular doctor?
- What are the risks involved?
- What if I am harmed?
- Are there any tests requiring painful shots or blood samples?
- What should I do if I want a friend/parent to join a study?
- Will I be paid?
- Will I be reimbursed for gas?
- What kinds of medical problems would prevent participation in the clinical trial?
- Do I have to talk to my health insurance company before enrolling in a study?
- What if I miss a dose?
- Can I drop out at any time?
- Are there placebos involved?
Phase I
Phase II
Phase III
Phase IV
Prostate Cancer Clinical Trials Consortium
The Prostate Cancer Clinical Trials Consortium (PCCTC) is a clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP), with its Coordinating Center headquartered at Memorial Sloan Kettering Cancer Center. The PCCTC is currently composed of 15 participating clinical research sites and 32 affiliated clinical research sites.
Visit the PCCTC site for trial information: www.pcctc.org
Open Trials
For a complete list of open trials in the United States, please visit:
Start the conversation about prostate cancer research. And keep making memories to last a lifetime.
Prostate cancer is the second most diagnosed cancer in men worldwide.
Even though some therapies for prostate cancer called androgen receptor signaling inhibitors (ARSIs) have been shown to help, it is common for patients to develop a resistance to these types of medications. This means that for some men with prostate cancer, treatment stops working. Because of this, continuing research is so important.
A new study for adults with prostate cancer is investigating a study drug called ONCT-534. ONCT-534 is designed to work differently, and doctors want to learn if it is safe and useful for individuals with metastatic castration-resistant prostate cancer (mCRPC).
To be eligible for this study, you must*:
• Be at least 18 years of age
• Have mCRPC
• Have cancer that has come back or stopped responding to treatment after taking certain ARSIs
*This is not a complete list of study requirements. If you are interested, the study doctor will review the full eligibility criteria with you.
To learn more about this study, visit https://www.clinicaltrials.gov/study/NCT05917470
ClinicalTrials.gov identifier: NCT05917470
The INDICATE Study (EA8191) – Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Based on PET Imaging
Do you have prostate cancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. In the EA8191/INDICATE study, all participants will receive the usual treatment for prostate cancer that recurs after surgery, which is radiation therapy (RT) to the prostate bed and pelvic lymph nodes, combined with short-term (6 months) androgen deprivation therapy (STAD), also sometimes referred to as hormone therapy. In addition:
– Some patients will receive additional PET imaging, depending on the results of their initial PET scan.
– Some patients will also receive a type of hormone therapy called apalutamide, which is approved by the FDA for treatment of your prostate cancer.
– Some patients, depending on the results of their initial PET scan, will receive metastasis-directed radiation therapy.
To decide which of these approaches is better, doctors on the study team will be looking to see if your cancer responds, and if it returns again, how much time passes after your treatment before it returns.
To learn more about this study and to find out if you may be eligible, please visit: https://www.clinicaltrials.gov/study/NCT04423211
ClinicalTrials.gov identifier: NCT04423211
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Merck is conducting this clinical trial to find out if the investigational medication pembrolizumab in combination with abiraterone and prednisone is safe and works to slow down or stop the growth of metastatic Castrate Resistant Prostate Cancer (mCPRC). Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. This trial is currently enrolling patients with mCRPC who have not received chemotherapy for mCRPC and have either not had prior second generation hormonal manipulation for mCRPC, or have previously been treated with enzalutamide for mCRPC and failed treatment or has become intolerant of the drug. Additional eligibility criteria will apply. Click here to learn more about this trial on the sponsor’s website.
To learn more about this study and to find out if you may be eligible, please visit: https://clinicaltrials.gov/ct2/show/NCT02861573
ClinicalTrials.gov Identifier: NCT02861573
MVT-601-049
Myovant Sciences is conducting a clinical study to learn about the safety and tolerability of relugolix in combination with medications approved for use in combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic castrate-sensitive prostate cancer (mCSPC), non-metastatic castrate-resistant prostate cancer (nmCRPC) and metastatic castrate-resistant prostate cancer (mCRPC).
Relugolix is an oral, FDA-approved medication. The clinical study will have three parts. Patients with advanced prostate cancer will participate in only one of the three parts of the clinical study.
Part 1: Relugolix in combination with abiraterone acetate and a corticosteroid
Part 2: Relugolix in combination with apalutamide
Part 3: Relugolix in combination with docetaxel with or without prednisone
Patients currently being treated with leuprolide acetate (Lupron® or Eligard®) or degarelix (Firmagon®) in combination with abiraterone acetate (Zytiga®)/fine-particle abiraterone acetate (Yonsa®), apalutamide (Erleada®), or docetaxel (Taxotere®) may be eligible to participate. Additional eligibility criteria will apply.
To learn more about this study please visit: https://clinicaltrials.gov/ct2/show/NCT04666129
ClinicalTrials.gov identifier: NCT04666129
Additional open trials can be found by going to:
Literature:
Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials
Tomasz M. Beer, MD
Larry Axmaker, Ed.D.
Written from both a patient and clinician perspective by Larry Axmaker, Ed.D., and Tomasz M. Beer, MD, a PCF-funded researcher, this book is an insightful resource for anyone considering clinical trials in addition to standard cancer therapy. Order Here »